





## 1.833.404.2392 Prescriber Help Desk 1.833.587.2012

**Online** 

Fax Completed Form To

covermymeds.com/main/ prior-authorization-forms/

## Request for Prior Authorization GRANULOCYTE COLONY STIMULATING FACTOR

(PLEASE PRINT – ACCURACY IS IMPORTANT)

	(I LEASE I KINT - ACCORACT IS II II OKT	<u>'</u>
IA Medicaid Member ID #	Patient name	DOB
Patient address		,
Provider NPI	Prescriber name	Phone
Prescriber address		Fax
Trescriber address		Tax
Pharmacy name	Address	Phone
Prescriber must complete all information above. It must be legible, correct, and complete or form will be returned.		
Pharmacy NPI	Pharmacy fax	NDC
granulocyte colony stimulating factor and therapy failure with a preferred	therapy with granulocyte colony stimulating agents will be authorized only for cases in whi agent(s). Laboratory values for complete bluctions. Dosage reduction and discontinuation	ch there is documentation of previous trial(s) ood and platelet count must be obtained as
Preferred       Non-Preferred         ☐ Fylnetra       ☐ Neupogen       ☐ Fulphila       ☐ Leukine       ☐ Rolvedon       ☐ Stimufend       ☐ Ziextenzo         ☐ Granix       ☐ Nyvepria       ☐ Neulasta       ☐ Nivestym       ☐ Udencya       ☐ Zarxio         ☐ Releuko       ☐ Releuko		
<del>_</del>		
Strength	Dosage Instructions	Quantity Days Supply
Diagnosis (or indication for the pro Prevention or treatment of febri Treatment of neutropenia in pat Mobilization of progenitor cells i chemotherapy. Treatment of congenital, cyclic, o		receiving myelosuppressive anticancer therapy. motherapy followed by a bone marrow transplant.
Diagnosis (or indication for the pro Prevention or treatment of febri Treatment of neutropenia in pat Mobilization of progenitor cells i chemotherapy. Treatment of congenital, cyclic, of On current chemotherapy drug(	duct):  le neutropenia in patients with malignancies who are ients with malignancies undergoing myeloablative che nto the peripheral blood stream for leukapheresis coor idiopathic neutropenia in symptomatic patients.  s) that would cause severe neutropenia (specify)	receiving myelosuppressive anticancer therapy. motherapy followed by a bone marrow transplant.
Diagnosis (or indication for the pro Prevention or treatment of febri Treatment of neutropenia in pat Mobilization of progenitor cells i chemotherapy. Treatment of congenital, cyclic, o On current chemotherapy drug( Other condition specify)  Absolute Neutrophil Count (ANC):	duct):  le neutropenia in patients with malignancies who are ients with malignancies undergoing myeloablative che nto the peripheral blood stream for leukapheresis coor idiopathic neutropenia in symptomatic patients.  s) that would cause severe neutropenia (specify)	receiving myelosuppressive anticancer therapy. motherapy followed by a bone marrow transplant. illections to be used after myeloablative
Diagnosis (or indication for the pro Prevention or treatment of febri Treatment of neutropenia in pat Mobilization of progenitor cells i chemotherapy. Treatment of congenital, cyclic, o On current chemotherapy drug( Other condition specify)  Absolute Neutrophil Count (ANC): Dates of routine CBC:	duct):  le neutropenia in patients with malignancies who are ients with malignancies undergoing myeloablative che nto the peripheral blood stream for leukapheresis cor idiopathic neutropenia in symptomatic patients.  s) that would cause severe neutropenia (specify)	receiving myelosuppressive anticancer therapy. motherapy followed by a bone marrow transplant. illections to be used after myeloablative
Diagnosis (or indication for the pro Prevention or treatment of febri Treatment of neutropenia in pat Mobilization of progenitor cells i chemotherapy. Treatment of congenital, cyclic, o On current chemotherapy drug( Other condition specify)  Absolute Neutrophil Count (ANC): Dates of routine CBC: Platelet Counts:	duct):  le neutropenia in patients with malignancies who are ients with malignancies undergoing myeloablative che nto the peripheral blood stream for leukapheresis coor idiopathic neutropenia in symptomatic patients.  s) that would cause severe neutropenia (specify)	receiving myelosuppressive anticancer therapy. motherapy followed by a bone marrow transplant. illections to be used after myeloablative
Diagnosis (or indication for the pro Prevention or treatment of febri Treatment of neutropenia in pat Mobilization of progenitor cells i chemotherapy. Treatment of congenital, cyclic, o On current chemotherapy drug( Other condition specify)  Absolute Neutrophil Count (ANC): Dates of routine CBC: Platelet Counts: Pertinent Lab data:	duct):  le neutropenia in patients with malignancies who are ients with malignancies undergoing myeloablative che nto the peripheral blood stream for leukapheresis cor idiopathic neutropenia in symptomatic patients.  s) that would cause severe neutropenia (specify)	receiving myelosuppressive anticancer therapy. motherapy followed by a bone marrow transplant. illections to be used after myeloablative
Diagnosis (or indication for the pro Prevention or treatment of febri Treatment of neutropenia in pat Mobilization of progenitor cells i chemotherapy. Treatment of congenital, cyclic, o On current chemotherapy drug( Other condition specify)  Absolute Neutrophil Count (ANC): Dates of routine CBC: Platelet Counts: Pertinent Lab data: Previous therapy (include drug name, see	duct):  le neutropenia in patients with malignancies who are ients with malignancies undergoing myeloablative che nto the peripheral blood stream for leukapheresis coor idiopathic neutropenia in symptomatic patients.  s) that would cause severe neutropenia (specify)	receiving myelosuppressive anticancer therapy. motherapy followed by a bone marrow transplant. illections to be used after myeloablative
Diagnosis (or indication for the pro Prevention or treatment of febri Treatment of neutropenia in pat Mobilization of progenitor cells i chemotherapy. Treatment of congenital, cyclic, o On current chemotherapy drug( Other condition specify)  Absolute Neutrophil Count (ANC): Dates of routine CBC: Platelet Counts: Pertinent Lab data: Previous therapy (include drug name, see a son for use of Non-Preferred drug	duct):  le neutropenia in patients with malignancies who are ients with malignancies undergoing myeloablative che nto the peripheral blood stream for leukapheresis cor idiopathic neutropenia in symptomatic patients.  s) that would cause severe neutropenia (specify)	receiving myelosuppressive anticancer therapy. motherapy followed by a bone marrow transplant. illections to be used after myeloablative
Diagnosis (or indication for the pro Prevention or treatment of febri Treatment of neutropenia in pat Mobilization of progenitor cells i chemotherapy. Treatment of congenital, cyclic, o On current chemotherapy drug( Other condition specify)  Absolute Neutrophil Count (ANC): Dates of routine CBC: Platelet Counts: Pertinent Lab data: Previous therapy (include drug name, see a son for use of Non-Preferred drug	duct):  le neutropenia in patients with malignancies who are ients with malignancies undergoing myeloablative che nto the peripheral blood stream for leukapheresis coor idiopathic neutropenia in symptomatic patients.  s) that would cause severe neutropenia (specify)	receiving myelosuppressive anticancer therapy. motherapy followed by a bone marrow transplant. illections to be used after myeloablative

**IMPORTANT NOTE:** In evaluating requests for prior authorization the consultant will consider the treatment from the standpoint of medical necessity only. If approval of this request is granted, this does not indicate that the member continues to be eligible for Medicaid. It is the responsibility of the provider who initiates the request for prior authorization to establish by inspection of the member's Medicaid eligibility card and, if necessary by contact with the county Department of Health and Human Services, that the member continues to be eligible for Medicaid.